


Research Article

Transcriptome and SARS-CoV-2 Biological Network Directed Analysis for Better Therapeutic Development

Om Prakash Sharma^{1*}, Ruchika Sharma² and Vinay Chandil²

Abstract

Background: It has been almost 3.5 years since the first SARS-CoV-2 virus was first reported in the city of Wuhan. While the FDA has approved a number of drugs for Covid-19, the presence of the disease and its symptoms underscores the continued demand for an improved treatment option to effectively address the existing challenges. In this study, our goal is to identify pivotal protein targets, strongly correlated across lung, blood, and peripheral blood mononuclear cell (PBMC) transcriptomics datasets, to suggest promising targets for comprehensive therapeutic development across multiple tissues.

Methods: Transcriptomics datasets were retrieved from Geo Omnibus (GEO). We use relevant datasets to identify the most significant and differentially expressed genes and integrated them into a Research graph called CovInt (a network of Covid-19) that includes all biological molecules associated in the network with their directionalities collected from publicly available and patient-derived multi-omics datasets from millions of unstructured and structured datasets such as publications, patents, grants, preclinical and clinical reports. CovInt utilizes powerful traversal, clustering and centrality algorithms to identify key connections in the pathophysiology of the disease and its treatments.

Results: Leveraging 3M+ connections, important interactions among key 42 drugs, 962 biological processes and molecular functions, 926 pathways, 897 phenotypes, 7103 proteins, 61 tissues were identified. This narrowed interactome was explored further using PageRank, lovain detection & strongly connected components (SSC) algorithms. In our analysis, 63 strongly connected communities were identified which gives us an understanding of hidden underlying mechanisms. We further explored this network to identify and triangulate the key proteins, metabolic pathways and associated risk factors that can regulate moderate to severe Covid-19 infections.

Conclusions: Our study suggests that CREB3L1, SOX2, UBR4, FLNC, ITPA, DLG3, ING4, TECR, NADH, SMAD, HUWE1, DDX17, CREBBP, RELA, HPSE, TRIM33, TNFSF13B are the key regulator proteins in PBMC, Blood and Lungs in Covid19 patients. These proteins are involved in ER-stress, cytokine signaling, T-Cell activation, Activation of NLRP3 Inflammation by SARS-CoV-2, JAK-STAT, IL-4, IL-13 pathways, MAPK signaling pathways, Activation of NMDA receptor & postsynaptic events and TGF- β signaling pathways. This set of proteins needs to be further investigated in experimental studies for better therapeutic design of Covid-19.

Affiliation:

¹Innoplexus AG, Frankfurter Str. 27, Eschborn, 65760 Germany

²Innoplexus Consulting Pvt. Ltd, 7th Floor, Midas Tower, Next to STPI Building, Phase 1, Hinjewadi Rajiv Gandhi, Infotech Park, Hinjewadi, Pune, Maharashtra 411057

*Corresponding author:

Om Prakash Sharma, Innoplexus AG, Frankfurter Str. 27, Eschborn, 65760 Germany.

Citation: Om Prakash Sharma, Ruchika Sharma and Vinay Chandil. Transcriptome and SARS-CoV-2 Biological Network Directed Analysis for Better Therapeutic Development. Fortune Journal of Health Sciences. 6 (2023): 403-421.

Received: October 11, 2023

Accepted: October 20, 2023

Published: October 30, 2023

Keywords: Covid-19; transcriptomic analysis; SARS-CoV-2 targets; differentially expressed genes; network analysis; target engagement; perturbed pathway

Introduction

The ongoing COVID-19 infection is still a major concern for most of the country and has made a serious impact on worldwide public health. The world has seen a number of mutational variants and as a consequence huge mortality and cases of hospitalization. The virus mostly affects the human breathing and immune system which ultimately leads to respiratory distress syndrome (ARDS), cardiac issues [1], multi-organ failure and eventually death [2]. The SARS-CoV-2 belongs to the Betacoronavirus group and in the past few years, we have seen how frequently this virus is constantly changing through multiple mutations and emerging as a new therapeutic challenge to the world by showing resistance to the available therapeutics and prevention vaccines [3 – 5]. We believe there are high chances that in future as well these viruses will get mutated and may cause serious health causes. Since December 2019, the virus has mutated significantly and transmitted rapidly all over the world. A number of mutations have been reported to date for SARS-CoV-2 which is classified by WHO and CDC in four different types (1) Variant Being Monitored (VBM) (2) Variant of Interest (VOI) (3) Variant of Concern (VOC) and (4) Variant of High Consequence (VOHC). As per European Centre for Disease Prevention and Control (ECDC), as of 17th March'2022, 1,145,785, alpha and 40,534 Beta, 4,226,252 Delta and 2,277,587 Omicron variants of concerned genomes have been isolated and processed [6]. The Variant of Concern is a class of variants that are spreading fast and making a severe impact on public health. Currently, the Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529)² variants are the only variants that fall in this group.

To date, a total of 5,401 interventional clinical studies are reported on clinicaltrial.gov and out of which 364 studies from Phase3 and 100 clinical studies from Phase-4 are completed. However, only limited therapeutics are approved so far to treat mild to moderate SARS-CoV-2 infection with huge unmet needs [7, 8] and treatment benefits with the frequent mutation are still a matter of concern. Due to the heterogeneity among various populations and diversification of SARS-CoV-2 mutations, it is an alarming situation to understand the crucial target engagement of the disease and uncover various underlying disease pathophysiology based on disease severity, stage, tissues, ages and patient populations. Several researchers have reported the importance of transcriptomic signature in response to infection [9]. Therefore, the transcriptome signature of SAR-CoV-2 infection could be one of the important parameters to identify the most crucial panel of targets engaged in the pathophysiology and severity of the disease. In this current research work, 15 high

throughput transcriptomics datasets were selected from the Gene Expression Omnibus (GEO) database. These datasets were further analyzed to predict the most significant DEGs that can differentiate between healthy and disease patients based on Blood, PBMC and Lung tissues datasets. Later, these genes were further evaluated through the in-house built Covid-19 interacting network (CovInt) to investigate their importance in SARS-CoV-2 pathophysiology. In order to identify these crucial regulatory genes, we leveraged various network scoring such as page rank algorithms and the popularity of molecules within the network. The present study aimed to identify the most significant panel of gene sets which can be used for better therapeutic development against Covid-19 infections.

Materials and Methods

Transcriptomics data collection and validation

Gene Expression analysis was carried out starting from the raw FastQ sequencing data downloaded from Gene Expression Omnibus (GEO) database [10]. We searched using “Severe acute respiratory syndrome coronavirus 2 [Organism] OR Covid-19 [All Fields] OR Severe acute respiratory syndrome coronavirus 2 [Organism] OR covid19 [All Fields] OR Severe acute respiratory syndrome coronavirus 2 [Organism] OR SARS-CoV-2 [All Fields] AND "Homo sapiens"[porgn] AND "gse"[Filter]” on 3rd Jan 2022 in the GEO database for SARS-CoV-2 associated expression datasets which results in “311” hits. Later, we applied filters on study types using Expression profiling by array and Expression profiling by high throughput sequencing (HTS) which results in 300 studies. These series were downloaded in .txt format from GEO omnibus data portal. The obtained file was converted into .csv format for further validation and classification in the Linux terminal using the below-mentioned syntax

```
sed 's/^$/@/' input_file.txt |tr "\n" "\t" | sed "s/@/\n/g -o output_file.csv
```

Later, we used our in-house developed AI-based tool to stratify and label samples based on their tissue types, study types and sub-indications. This in-house developed model also removes studies with less than 3 samples, samples with nonspecific disease names, studies with only healthy data, superseries and other studies such as snRNA-seq, single-cell, and missing SRA id datasets and classified as irrelevant/insignificant studies. The remaining relevant studies were further analyzed for differentially expressed genes. All relevant studies were carried forward for further analysis.

Transcriptomics data analysis

Relevant expression datasets were further processed for further quality control using Trim-galore [11] which trims off all low-quality bases from the 3' end of the reads before adapter removal. In the next step, all adapters and short

sequences (20 bp) from the 3' end of reads were filtered. Estimating transcript abundance from RNA-seq reads is a fundamental and crucial step in transcriptomic analysis. We used Salmon [12] as a tool to quantify transcripts based on the reference transcriptome build GRCh38 downloaded from NCBI and indexed using Salmon. The number of reads per transcript obtained for each sample from previous steps was directly used as an input to calculate Differentially Expressed Genes (DEGs). DEG analysis was carried out by using the DESeq2 [13] Bioconductor package v1.34.0, which calculated Log2FC (log 2-fold change) values per gene including p-values, adjusted p-value and base mean values. We applied a cut-off p-value for ≤ 0.005 and Log2FC value > 1.5 for further analysis.

Enrichment of DEGs and development of CoVint network for molecular connections

Identified differentially expressed gene from the previous study was further used for the enrichment of associated pathways, molecular connections and disease-protein-associated relevant articles through Ontosight® Discover [14, 15] and Ontosight® Explore (<https://www.innoplexus.com/blog/accelerate-your-research-and-discovery-in-life-sciences/>). The overall transcriptomics analysis process is shown in Figure 1.

Ontosight Explore® [16, 17] consist of 4.2 M+ chemicals and drug, 250 K+ disease, 560 K+ proteins, 6 K+ pathways

and 39 K+ number of molecular connections extracted from various literature and publicly available curated database including Covid-19 pathways from WikiPathways [18] and build a comprehensive SARS-CoV-2 protein-protein interaction network called CoVint (Covid Interactome) by maintaining their types of relationships and directionality of reactions in a neo4j v4.3.3 graph database. The overall schema of CovInt has been shown in Figure 2a. In this current study, Ontosight Discover® and Explore® were used to identify the molecular connections of prioritized DEGs and their significance in Covid-19 pathophysiology.

Here, CoVint consists of 39 K+ molecular connections associated with SARS-CoV-2 (Figure 2b). These connections are then further traversed using the neo4j browser and visualized using neo4j's bloom application. We superimposed expression values of each DEG in the CoVint biological network to determine the flow of expression and identify important perturbations in the network. This helped us in taking into account the effect of expression change from healthy to disease on other molecular pathways and entities.

To prioritize DEGs We used a Hyperlink-Induced Topic Search (HITS) algorithm to check the flow of expression from a DEG in the network which helped in identifying the authority DEGs that have a greater influence. The developed network is presented in Figure 2b.




Figure 1: Flow diagram outlining COVID-19 RNA-seq data analysis process.




Figure 2: (a) Represents the schema of various molecular connections in the CoVint network built using Neo4J software.

(b) A SARS-CoV-2 differentially expressed gene and its biological connection. Here, the yellow color demonstrates covid19 disease, while related biological pathways are highlighted in blue color, clinical and biological function is shown in red colors, interacting partner proteins are shown in light brown color, tissues are in green and other entities are shown in grey color.

Single pathway network (SPN) analysis and GO enrichment

We analyzed each covid19 pathway (P) by superimposing its protein associations (g1, g2...gn) with their interactions such that

$$PI(g(k)) = [i(k)(1), i(k)(2)...i(k)(m)] \text{ where } k \leq n$$

Thus the imposed pathway network consisted of 1 pathway node (P), L = union of (g, PI(g)) protein nodes and (P)-[:Associated with]->(L), (g)-[:Interacts]->(PI(g)) relations. This concluded the generation of our pathway network. Then we mapped the differentially expressed gene on this network to find the importance and influence of this pathway (W(p)) using a greedy influence maximization approach where a group of proteins that when expressed may induce an effect of the pathway.

In order to understand the biological functions of predicted DEGs, we performed Gene Ontology (GO) [19]. We first downloaded all GO datasets (<http://geneontology.org/docs/downloads/>) with their associated genes, later we performed statistical analysis to enrich Gene ontology for the identified DEGs. Identified genes were classified into GO categories as a biological process (BP), molecular function (MF) and cellular component (CC). Top enriched GO was identified based on the $p < 0.05$ as the cut-off criterion and various graphs were generated to understand the overlapped genes and Gene ontologies involved in disease pathophysiology. We further used this information to triangulate this information with the CoVint network and evaluated the top marker using published scientific reports.

Results

Transcriptomics data collection and analysis

In order to perform transcriptomics analysis, we first queried the GEO Omnibus database to identify the most relevant datasets for our study. It results in 311 hits for our given query against COVID-19. The details of various types of datasets have been shown in Table 1.

However, upon validation and stratification of relevant samples, we remained with 16 studies which we were able to include in our further study. The remaining 295 studies were excluded from our further analysis (Supplementary Table 1). In total, we identified 12 high throughput sequencing studies and 4 Microarray studies. 2 out of the 4 Microarray studies were done on immune-specific probes, therefore due to missing data we discarded those studies (Table 1). Among the 12 HTS studies, 5 studies were from Blood samples, 2 studies were from Peripheral Blood Mononuclear Cells (PBMCs), 2 studies were from Lung Tissue with a significant number of studies which we carried forward for further analysis. In total, we identified 201 healthy volunteers and 575 disease samples where we had a significant amount of data to generate confident results. Single studies from other sample sources such as Nasal Swabs, Brain, and Platelets were discarded due to a limited number of experiments (Table 2).

Identification of DEGs

Based on the cut-off criteria of $\log_2 FC \geq 1.5$ for upregulated and ≤ -1.5 for downregulated and $\text{adj } P\text{-value} \leq 0.05$. We identified 925, 1336 and 50 upregulated genes and

265, 938 and 2217 downregulated genes in Blood, PBMC and Lung respectively and a total of 139 overlapping DEGs were identified as shown in Figure 3a obtained from the Lung, Blood and PBMC samples. The DEGs identified for each of the tissues separately, are represented through volcano plots as shown in Figures 3b, 3c and 3d respectively. The list of identified DEGs can be found here as Supplementary File 2.

The expression level of each sample is shown in the Volcano plot in Figure-3b, 5c and 5d. Moreover, the heatmap of DEGs demonstrates that these DEGs could distinguish the control and other samples.

Gene Functional Enrichment from Top Degs of Blood, PBMC and Lung Tissues

Blood tissues

GO enrichment of top upregulated gene suggests that Detection of chemical stimulus involved in sensory perception

Table 1: SARS-CoV-2 associated different datasets

#	Study type	Studies
1	Expression profiling by array	12
2	Expression profiling by high throughput sequencing	300
3	Genome binding/occupancy profiling by array	0
4	Genome binding/occupancy profiling by high throughput sequencing	7
5	Methylation profiling by array	1
6	Methylation profiling by high throughput sequencing	1
7	Non-coding RNA profiling by array	0
8	Non-coding RNA profiling by high throughput sequencing	4

of smell (GO:0050911), Positive regulation of gene expression (GO:0010628), Negative regulation of apoptotic process (GO:0043066), Response to nutrient (GO:0007584), Cellular response to glucose stimulus (GO:0071333) (**Figure 4A.1**), whereas, GO enrichment of top downregulation gene suggests that mRNA splicing, via spliceosome (GO:0000398), G protein-coupled receptor signaling pathway (GO:0007186), Defense response (GO:0006952), Positive regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043123), I-kappaB kinase/NF-kappaB signaling (GO:0007249) are the major biological processes (**Figure 4A.4**).

Olfactory receptor activity (GO:0004984), Identical protein binding (GO:0042802), ATP binding (GO:0005524), Extracellular matrix structural constituent (GO:0005201), Protein homodimerization activity (GO:0042803) are the top five molecular functions of identified upregulated DEGs also demonstrated in **Figure 4A.2**. and Identical protein binding (GO:0042802), Protein binding (GO:0005515), ATP binding (GO:0005524), Aminoacyl-tRNA editing activity (GO:0002161), Peptide antigen binding (GO:0042605) are the top molecular functions which influenced due to downregulation of identified DEGs (**Figure 4A.5**).

Similarly, Extracellular exosome (GO:0070062), Membrane (GO:0016020), Cytosol (GO:0005829), Apical plasma membrane (GO:0016324), Cytoplasm (GO:0005737) are the top cellular components in blood tissue from upregulated DEGs (**Figure 4A.3**) and Cytosol (GO:0005829), Extracellular exosome (GO:0070062), Membrane (GO:0016020), Mitochondrial matrix (GO:0005759), Cytoplasm (GO:0005737) are the top cellular components influenced by downregulated DEGs (**Figure 4A.6**).

Table 2: Characteristics of High-throughput studies datasets considered in this study

#	Study type	Studies	GSE series	Healthy	Disease	Total Sample	Considered for study?
1	PBMC	2	GSE166253	16	10	94	Yes
			GSE152418	34	34		Yes
2	Blood	5	GSE185557	18	21	39	Yes
			GSE166190	16	82	98	Yes
			GSE169687	14	138	152	Yes
			GSE161731	19	58	77	Yes
			GSE161777	13	14	27	Yes
3	Lung	2	GSE151764	16	34	50	Yes
			GSE150316	15	83	98	Yes
4	Nasal Swabs	1	GSE166530	5	36	41	No
5	Brain	1	GSE179923	6	1	7	No
6	Platelets	1	GSE176480	10	8	18	No

Identified samples were further normalized using Limma-remove batch effect package [20] and visualization was done using PCA plot. Since we used DESeq2 for getting DEGs, where expression values are normalized using the median-ratios method, we used the Limma package to analyze the data batches in detail and how the data looks after removing the batch effect.




Figure 3: (a) Venn diagram of identified DEGs, 139 overlapped DEGs from Blood, PBMC and Lung samples. (b) Volcano plot of identified DEGs from blood tissue samples (c) Volcano plot of PBMC samples (d) Volcano plot of Lung tissue samples. Here, the red color demonstrates downregulated genes, and the green color demonstrates upregulation of genes.

Peripheral blood mononuclear cell (PBMC)

Top biological processes enriched from upregulated DEGs are PBMC are Positive regulation of transcription by RNA polymerase II (GO:0045944), Detection of chemical stimulus involved in sensory perception of smell (GO:0050911), Negative regulation of apoptotic process (GO:0043066), Response to hypoxia (GO:0001666), Aging (GO:0007568) have been also shown in **Figure 4B.1** and downregulation of DEGs G-protein-coupled receptor signaling pathway (GO:0007186), Regulation of transcription by RNA polymerase II (GO:0006357), Biological process (GO:0008150), Positive regulation of B cell proliferation (GO:0030890) have been shown in **Figure 4B.4**. Olfactory receptor activity (GO:0004984), Protein binding (GO:0005515), Chromatin binding (GO:0003682), Identical protein binding (GO:0042802), Protein kinase binding (GO:0019901) were top molecular functions from upregulated DEGs (**Figure 4B.2**) whereas G-protein-coupled receptor activity (GO:0004930), Protein binding (GO:0005515), ATP binding (GO:0005524), Identical protein binding (GO:0042802), Metal ion binding (GO:0046872) are from Downregulated DEGs (**Figure 4B.5**)

Similarly, Cytosol (GO:0005829), Nucleoplasm (GO:0005654), Membrane (GO:0016020), Extracellular

exosome (GO:0070062), Golgi apparatus (GO:0005794) are the top cellular component enriched from the upregulated PBMC genes (**Figure 4B.3**). Whereas Cytosol (GO:0005829), Membrane (GO:0016020), Extracellular exosome (GO:0070062), Mitochondrial matrix (GO:0005759), Mitochondrion (GO:0005739) are the top enriched CC (**Figure 4B.6**) from top downregulated DEGs. We observed in both types of DEGs cytosol, the Extracellular exosome and Membrane are the most important CC that was influenced (**Figure 4B**).

Lung tissues

GO enrichment from top downregulated DEGs from lung tissues revealed Positive regulation of interferon-gamma production (GO:0032729), Adaptive immune response (GO:0002250), Inflammatory response (GO:0006954), Positive regulation of T cell proliferation (GO:0042102), Positive regulation of NMDA glutamate receptor activity (GO:1904783) are the major biological processes (**Figure 4C.1**) and Heart development (GO:0007507), G protein-coupled receptor signaling pathway (GO:0007186), Osteoblast differentiation (GO:0001649), Positive regulation of gene expression (GO:0010628), Negative regulation of cell population proliferation (GO:0008285) are the top BP




Figure 4: The cluster of significant enriched GO terms for upregulated and downregulated DEGs from (A) Lung tissues (B) Blood tissues and (C) PBMC tissues

from downregulated DEGs (**Figure 4C.4**). Similarly, the top cellular components (CC) from the upregulated genes are the External side of the plasma membrane (GO:0009897), MHC class II protein complex (GO:0042613), Cell surface (GO:0009986), Alpha-beta T cell receptor complex (GO:0042105), Extracellular region(GO:0005576) (**Figure 4C.2**) and Extracellular matrix structural constituent (GO:0005201), ATP binding (GO:0005524), G protein-coupled receptor activity (GO:0004930), Protein binding (GO:0005515), Identical protein binding (GO:0042802) for downregulated DEGs (**Figure 4C.6**). External side of the plasma membrane (GO:0009897), MHC class II protein complex (GO:0042613), Cell surface (GO:0009986), Alpha-beta T cell receptor complex (GO:0042105), Extracellular region (GO:0005576) (**Figure 4C.3**) are top CC from upregulated Genes and Extracellular exosome (GO:0070062), Collagen-containing extracellular matrix (GO:0062023), Membrane (GO:0016020), Cytosol (GO:0005829), Endoplasmic reticulum lumen (GO:0005788) are top CC from downregulated DEGs (**Figure 4C.6**). In order to understand the role and involvement of identified genes and enriched BP, MF and CC, we performed a pathway over-representation study (Figure 9). Our study revealed that the Jak-STAT signaling pathway [21], Cytokine-Cytokine receptor interactions [22], MAPK signaling pathway [23], Lung Fibrosis [24–26], Chemokine signaling pathway [24], Toll-like receptor signaling are the major pathways that were

represented by identified DEGs and GO analysis. These pathways are well known and reported previously to play a crucial role in SARS-CoV-2-associated pathophysiology (Figure 5).

Network analysis

The identified DEGs were further explored in the CovInt network to understand their biological connections and their importance in the sub-network. Functional and CoVint network analysis revealed MAGED1, FBXO7, ATAD3A, TECR, CCDC8, CDC14A, TERF2IP, FBXW7, RNF123, CAND1, USP7, SMC4, HIF1A, TRIM63, CUL1 as the top 15 hub genes from blood tissues (Figure 6A) and IKBKG, CTDTP1, TNIK, BTRC, FBXW11, STUB1, NCOR2, LRRK2, HPSE, FHOD1, CCDC8, ARFGEF2, TRRAP, NDUFAF1, CBY1 (Figure 6B) from PBMC.

Whereas, PLEKHA4, CHCHD2, SUPT16H, LRRK2, PTRH2, STUB1, CCDC8, UBQLN1, SMC3, UBQLN2, MAP1LC3B, DOLK, AFG3L2, RBM8A, TBK1 are the top 15 hub genes from lung tissues (Figure 6C). We identified multiple clusters and sub-networks of various SARS-CoV-2-associated genes which were further prioritized based on the LogFc value, Network Score, target overlap count with covid-19 pathways and p-value score parameters. We estimated the relative rank for each parameter using Microsoft excel as shown below -




Figure 5: Enriched molecular pathways from the top 15 GO of BP, MF and CC. Here, XX color represents Biological processes, YY represents Cellular components and ZZ color represents Molecular functions. The bar of these pathways was represented through the overlap of identified GO genes with molecular pathways.




Figure 6: Heatmap of DEGs in (A) Blood (B) PBMC and (C) Lung sample. Each row represents a single gene, and each column represents a sample. Disease-associated samples are highlighted in red boxes whereas healthy samples are demonstrated in green boxes. The color scale shows the relative gene expression in certain slides. Green represents high relative expression levels and red indicates low relative expression levels.

Table 3: The DEGs of merged datasets from the blood sample with the applied criteria of p-value <0.05 and $|\log_2FC| \geq 1.5$, network score and directionality of regulations. The table is sorted based on the consolidated ranking score.

Blood tissues							
#	Gene Symbol	Gene Name	Network Score	Gene Expression	Direction	p-value	Relative ranking
1	SLC25A13	Solute carrier family 25 member 13	1.254	-4.706	down	2.60E-02	1
2	FBXW7	F-box and WD repeat domain containing 7	1.866	-3.325	down	4.30E-06	2
3	NOD2	Nucleotide binding oligomerization domain containing 2	0.969	-3.862	down	2.85E-08	3
4	CREB3L1	cAMP responsive element binding protein 3 like 1	1.091	6.338	up	3.93E-10	4
5	CDC14A	cell division cycle 14A	2.063	5.07	up	9.42E-16	5
6	SMC4	Structural maintenance of chromosomes 4	1.487	5.147	up	5.35E-05	6
7	CFL2	Cofilin 2	1.276	-2.58	down	4.21E-04	7
8	MAGED1	MAGE family member D1	8.364	-2.206	down	5.36E-04	8
9	ITPA	Inosine triphosphatase	0.758	-3.788	down	3.05E-08	9
10	DLG3	Discs large MAGUK scaffold protein 3	0.678	-4.79	down	7.53E-04	10
11	ING4	Inhibitor of growth family member 4	0.873	-2.853	down	1.10E-02	11
12	TECR	Trans-2,3-enoyl-CoA reductase	2.586	-2.093	down	6.00E-07	12
13	RELA	RELA proto-oncogene, NF-kB subunit	1.168	4.78	up	2.82E-06	13
14	CDH1	Cadherin 1	0.829	5.59	up	3.78E-06	14
15	ATAD3A	ATPase family AAA domain containing 3A	2.651	-1.959	down	4.50E-03	15
16	FBXO7	F-box protein 7	8.101	4.215	up	2.20E-30	16
17	ACAD8	Acyl-CoA dehydrogenase family member 8	0.807	-2.499	down	5.51E-03	17
18	RASSF1	Ras association domain family member 1	0.605	-3.601	down	1.69E-31	18
19	SOX2	SRY-box transcription factor 2	0.783	5.018	up	9.94E-10	19
20	IGSF8	Immunoglobulin superfamily member 8	0.561	-4.588	down	3.06E-09	20
21	MID2	Midline 2	0.911	-2.177	down	1.53E-02	21
22	CUL1	Cullin 1	1.39	4.193	up	1.26E-06	22
23	SP110	SP110 nuclear body protein	0.493	-19.754	down	3.36E-29	23
24	EHMT1	Euchromatic histone lysine methyltransferase 1	0.66	-2.737	down	4.53E-07	24
25	NODAL	Nodal growth differentiation factor	0.8	4.751	up	1.38E-07	25
26	PPAN	Peter pan homolog	0.899	-2.07	down	2.08E-04	26
27	PRDM16	PR/SET domain 16	1.155	4.182	up	1.86E-09	27
28	FAM118B	Family with sequence similarity 118 member B	0.466	-5.761	down	6.92E-35	28

29	IFT172	Intraflagellar transport 172	0.491	-3.891	down	4.08E-02	29
30	SYNC	Syncoilin, intermediate filament protein	0.475	7.565	up	2.75E-90	30
31	UHRF1	Ubiquitin like with PHD and ring finger domains 1	0.614	5.168	up	2.17E-08	31
32	SH3GLB1	SH3 domain containing GRB2 like, endophilin B1	1.361	3.857	up	3.10E-16	32
33	GANAB	Glucosidase II alpha subunit	0.465	-4.146	down	8.93E-09	33
34	TAF15	TATA-box binding protein associated factor 15	1.058	-1.779	down	1.74E-61	34
35	PTK2B	Protein tyrosine kinase 2 beta	0.576	5.093	up	2.11E-32	35
36	HSPB8	Heat shock protein family B (small) member 8	1.148	3.86	up	8.53E-06	36
37	DIABLO	Diablo IAP-binding mitochondrial protein	1.15	-1.59	down	7.20E-03	37
38	PARK7	Parkinsonism associated deglycase	0.715	-1.97	down	7.36E-23	38
39	BIRC7	Baculoviral IAP repeat containing 7	0.806	-1.829	down	2.62E-02	39
40	RUFY1	RUN and FYVE domain containing 1	0.422	-6.191	down	5.96E-06	40
41	CLUAP1	Clusterin associated protein 1	1.019	3.774	up	7.16E-06	41
42	PPIE	Peptidylprolyl isomerase E	0.631	-2.022	down	1.15E-04	42
43	KCTD3	Potassium channel tetramerization domain containing 3	1.34	3.435	up	1.59E-02	43
44	PPT1	Palmitoyl-protein thioesterase 1	0.45	5.673	up	7.61E-242	44
45	BRD7	Bromodomain containing 7	0.513	4.73	up	3.79E-155	45
46	UBR4	Ubiquitin protein ligase E3 component n-recognin 4	0.443	-2.879	down	8.39E-13	46
47	FLNC	Filamin C	0.605	4.328	up	4.34E-07	47
48	AGAP3	ArfGAP with GTPase domain, ankyrin repeat and PH domain 3	0.419	-3.2	down	3.07E-07	48
49	MYO5B	Myosin VB	0.802	3.727	up	6.06E-13	49
50	EFEMP1	EGF containing fibulin extracellular matrix protein 1	0.395	7.234	up	2.34E-03	50

Relative ranking = RANK(\$A2,\$A\$2:\$A\$N)

Here, A represents the name of the column and “N” represents the number of rows

And named as “Relative gene expression ranking” for LogFC, “Covid-19-associated pathway” for covid-19 pathways, “Relative network score” for Network Score and estimated a consolidated score using the below-mentioned formula where p-value was used as a qualifying parameter.

Consolidated Score =

$$(G2 \times 60 \div 100) + (H2 \times 30 \div 100) + (J2 \times 10 \div 100)$$

Here, G2 stands for CovInt network Rank; H2 stands for relative Expression Ranking and J2 stands for relative covid-19 associated Pathway ranking. Based on relative ranking the top 50 relevant DEGs from Blood have been

shown in Table 3, PBMC in Table 4 and Lung tissues in Table 5.

Transcriptomics profile analysis of Whole Blood, PBMC and lung suggested dysregulation of CREB3L1, SOX2, UBR4 and FLNC transcription factor (Figure 7). Several investigators has reported dysregulation of CREB3L1 in ER stress during the Covid-19 infections [27, 28] whereas SOX2 is known to be a bronchus progenitor marker gene [29–31] that is involved in cytokine-mediated signaling pathway [32] and play an important role in lung fibrosis [33, 34]. Another common transcription factor identified from this analysis is UBR4 which is an E3 ubiquitin ligase and was found to be involved in the membrane morphogenesis autophagy process during the cytokine storm [35]. In our study, we found UBR4 as significantly dysregulated in Covid-19 infections and can be used as a potential therapeutic target for Covid-19.

UBR4 is previously reported as an important protein to be involved in the transportation of viral glycoproteins to the cell membrane and promotes replication of Influenza A virus [36]. Our study revealed a similar role of UBR4 in Covid-19 infections.

From blood tissue transcriptomics analysis, we identified Inosine Triphosphatase (ITPA) as one of the top transcription factors associated that are downregulated by -3.788 FoldChain as compared to a healthy patient. Multiple mutations are already reported in these genes such as rs1161447593, rs12980275 and rs8099917 which leads to a certain reduction in the ITPA expression associated with Hepatitis C virus response [37]. The role of ITPA can be further explored in SARS-CoV-2 infections. The second genetic marker is DLG3 which is found to be downregulated through our analysis with a Log2FC value of -4.790. DLG3 is recognized by SARS-CoV-2, E protein, however, its role still needs to be explored further [38]. Inhibitor of growth family member 4 (ING4) is

another interesting transcription factor that is downregulated (-2.853) in the disease samples. It interacts with the CXCL8 gene and regulates cytokine during the cytokine storm inflammatory response.

The expression of Trans-2,3-Enoyl-CoA Reductase (TECR) is downregulated (-2.093) in disease conditions. Activator of the TECR gene could be an interesting therapeutic target against Covid-19. RELA is another important key transcription factor that comes out from our analysis which is significantly upregulated (4.780) during the SARS-CoV-2 infection. RELA initiates TLR4 mediated NF-κB signaling pathway to activate IL-8 expression and thus regulates the IFN response [39]. Interestingly, upon investigation, we identified that these molecules are highly connected to each other and involved in various covid-19 infection-associated pathways such as Activation of NLRP3 inflammation, Renin-angiotensin Aldosterone system, Cytokine-cytokine receptor, MAPK signaling and Integrin signaling pathways (Figure 8).




Figure 7: Unique dysregulated gene from Blood, PBMC and Lung sample

Transcriptomics analysis from PBMC samples revealed HPSE is generally upregulated during Covid-19 with Log2FC of 7.315, it is involved in pro-inflammatory glycoalk generation that promotes chemokines, cytokines, and leukocytes binding to the endothelial cell surface. Inhibition of HPSE restricts HPSE activity and benefits Covid-19 patients [40] and other lung-associated diseases [41].

Tripartite Motif Containing 33 (TRIM33) is another interesting transcription factor that is found to be overexpressed (6.609) in our study. It regulates the proinflammatory function of Th17 cells [42]. Th17 cells are known to play an important role in COVID-19 pathogenesis by triggering cytokine cascade and inducing Th2 responses during the infection which leads to Treg cell suppression^{43,44}.

However, two important genes NADH and SMAD were identified as crucial hub genes from network analysis that can be activated for better therapeutic effects. Firstly, NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 (NDUFA12) which is an accessory subunit

of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) is found to be downregulated with a -6.035 FoldChain during the SARS-COV-2 viral infection sample from our study. Secondly, SMAD proteins are down-regulated in our study -8.572, which is known to be involved in TGF- β signaling pathways and pulmonary fibrosis⁴⁵.

Negative regulations of SMAD2 lead to lung injury and upregulation of SMAD2 may trigger TGF- β signaling pathways that may lead to the downregulation of angiotensin-converting enzyme 2(ACE2) receptor and limit the spike protein interaction with ACE2 in the early phase. Other interesting genes from PBMC sample analysis were come out from our analysis are FBXW7, SMC4, CFL2, ATAD3A, ACAD8, RASSF1, SOX2, IGSF8, SP110, EHMT1, NODAL, PPAN, FAM118B, IFT172, SYNC, SH3GLB1, PTK2B, BIRC7, RUFY1, CLUAP1, PPT1, and AGAP3 that need to be investigated further for their role in SARS-CoV-2 infections.




Figure 8: Molecular connections of the top dysregulated gene from the Blood sample. Here, upregulated proteins are shown in the green bubbles and down-regulated proteins are shown in red color and neutral genes are demonstrated in gray color. All biological pathways are highlighted in yellow color. Covid-19 associated pathways are labeled using blue text to differentiate the sub-clustered and associated genes.




Figure 9: (A) Molecular connections of the top dysregulated gene from PBMC sample. Here, upregulated proteins are shown in the green bubbles and down-regulated proteins are shown in red color and neutral genes are demonstrated in grey color. All biological pathways are highlighted in yellow color. Covid-19 associated pathways are labeled using blue text to differentiate the sub-clustered and associated genes. (B) Dysregulated genes from PBMC samples compared to healthy volunteers.

Lung tissues are the most important organ that gets affected during this disease. We identified TNF Superfamily Member 13B (TNFSF13B) as the most important transcription factor that is significantly differentially expressed in liver tissues with 2.955 Log2FC as a defense response suggesting its potential role in disease pathophysiological relations in SARS-CoV-2 infections [46]. It is supposed to activate B-cell and secretes antibodies into the blood and lung tissues that protect against pathogens and viral infection [47]. Whereas, Inducible T Cell Costimulator (ICOS) plays an important role in Tfh cell activation and high-affinity antibodies generation. In our study, we found it is significantly upregulated in disease conditions by 2.314 Log2FC and has multiple direct connections in the CoVint network. Various investigators have previously reported that downregulation of ICOS transcription factor significantly reduces Tfh cells [48–50] may lead to B cell differentiation and effective promotion of humoral immune responses [51] and helps in clearing life-threatening viruses including SARS-CoV-2. Therefore, potential inhibitors can be further explored for these proposed targets (Figure 10).

Lung tissues have also shown several genes that are significantly downregulated in disease conditions and especially in lung tissues. E3 ubiquitin-protein ligase

(HUWE1) is one of them. It mediates ubiquitination and subsequent proteasomal degradation of target proteins [52–54]. Previously, the HUWE1 gene was reported to induce cell apoptosis in MERS-CoV ORF3 via ubiquitination. Activation of HUWE1 can play an antiviral role in host immunity [102] and can be further explored for potential therapeutic candidature. We have also identified another important transcriptional factor gene DDX17 that is significantly downregulated in our studied sample with a -15.742 Log2 (fold change). It was also scored as an important protein from our network analysis which represents this protein as a potential biomarker for SARS-CoV-2. DEAD-box (DDX) RNA helicases play a very crucial role in the stage of Covid-19 infection and therefore can be used as positive or negative regulators in different levels of DDX-mediated viral replication steps.

We also identified Endothelial PAS domain-containing protein 1 (EPAS1) also known as HIF2A is an important transcription factor that is involved in the regulation of oxygen level during the disease condition. However, inhibition of EPAS1 may not benefit in the early stage Covid-19 infection but may serve as a promising treatment target post-Covid-19 complication [56]. Another important protein

Table 4: The DEGs of merged datasets from PBMC sample with the applied criteria of p-value <0.05 and $|\log_2FC| \geq 1.5$, network score and directionality of regulations

PBMC Tissues							
#	Gene Symbol	Gene Name	Network Score	Gene Expression	Direction	p-value	Relative ranking
1	FHOD1	Formin homology 2 domain containing 1	4.261	-10.042	down	1.58E-75	1
2	HPSE	Heparanase	4.538	7.315	up	3.11E-42	2
3	MAD2L2	Mitotic arrest deficient 2 like 2	3.446	-6.16	down	5.81E-184	3
4	DCPS	Decapping enzyme, scavenger	2.341	-6.662	down	1.28E-119	4
5	SMAD2	SMAD family member 2	1.412	-8.572	down	1.16E-13	5
6	TRIM33	Tripartite motif containing 33	2.441	6.609	up	6.99E-09	6
7	CHCHD2	Coiled-coil-helix-coiled-coil-helix domain containing 2	2.181	-5.569	down	0.00E+00	7
8	NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	1.766	-6.035	down	2.04E-239	8
9	ATXN10	Spinocerebellar ataxia type 10 protein	1.494	-6.501	down	0.00E+00	9
10	CENPJ	Centromere protein J	1.681	7.13	up	5.83E-11	10
11	MALT1	MALT1 paracaspase	1.082	-9.366	down	5.14E-58	11
12	LRCH1	Leucine rich repeats and calponin homology domain containing 1	2.253	-4.978	down	4.06E-12	12
13	USP7	Ubiquitin specific peptidase 7	2.565	6.044	up	5.45E-25	13
14	TELO2	Telomere maintenance 2	2.333	-4.878	down	1.16E-79	14
15	NOTCH3	Notch receptor 3	1.825	6.635	up	4.52E-04	15
16	MYBBP1A	MYB binding protein 1a	1.126	-7.007	down	2.66E-120	16
17	RBM28	RNA binding motif protein 28	0.912	-10.38	down	1.71E-85	17
18	TCTN3	Tectonic family member 3	1.113	-6.302	down	2.98E-136	18
19	LARS1	Leucyl-tRNA synthetase 1	2.282	-4.471	down	2.30E-08	19
20	TMEM216	Transmembrane protein 216	2.404	-4.387	down	1.57E-18	20
21	PRMT1	Protein arginine methyltransferase 1	1.405	-4.939	down	4.54E-30	21
22	TAB2	TGF-beta activated kinase 1 (MAP3K7) binding protein 2	0.867	8.956	up	9.37E-18	22
23	EPAS1	Endothelial PAS domain protein 1	1.154	6.638	up	3.94E-16	23
24	ZNF408	Zinc finger protein 408	1.149	-5.169	down	2.00E-56	24
25	STUB1	STIP1 homology and U-box containing protein 1	5.134	-3.738	down	0.00E+00	25
26	COG5	Component of oligomeric golgi complex 5	1.162	6.356	up	2.09E-17	26
27	RIF1	Replication timing regulatory factor 1	0.746	25.494	up	2.57E-42	27
28	IFT52	Intraflagellar transport 52	1.139	6.267	up	1.18E-13	28
29	HBS1L	HBS1 like translational GTPase	0.796	-7.863	down	1.08E-43	29
30	AUP1	AUP1 lipid droplet regulating VLDL assembly factor	3.445	4.731	up	6.28E-112	30
31	CC2D2A	Coiled-coil and C2 domain containing 2A	1.629	5.348	up	1.84E-03	31

32	NFS1	NFS1 cysteine desulfurase	1.362	-4.557	down	1.56E-11	32
33	GPATCH8	G-patch domain containing 8	0.76	9.194	up	2.04E-38	33
34	CLUAP1	Clusterin associated protein 1	1.358	5.496	up	1.52E-05	34
35	QKI	QKI, KH domain containing RNA binding	0.912	6.989	up	2.23E-11	35
36	RELA	RELA proto-oncogene, NF-kB subunit	1.465	-4.249	down	3.24E-55	36
37	GMPPB	GDP-mannose pyrophosphorylase B	1.341	-4.415	down	4.22E-198	37
38	MFF	Mitochondrial fission factor	0.872	-5.811	down	2.44E-19	38
39	DYNC1LI1	Dynein cytoplasmic 1 light intermediate chain 1	1.883	-3.872	down	1.30E-203	39
40	NDE1	nudE neurodevelopment protein 1	0.83	-6.026	down	6.30E-238	40
41	CD81	CD81 molecule	1.037	-4.857	down	8.65E-53	41
42	FBXW7	F-box and WD repeat domain containing 7	1.78	-3.848	down	7.36E-06	42
43	DYRK1A	Dual specificity tyrosine phosphorylation regulated kinase 1A	0.859	6.837	up	2.02E-56	43
44	FANCD2	FA complementation group D2	0.995	6.104	up	9.67E-19	44
45	NT5C3A	5'-nucleotidase, cytosolic IIIA	0.774	7.563	up	1.28E-41	45
46	IKBKG	Inhibitor of nuclear factor kappa B kinase regulatory subunit gamma	15.098	4.174	up	5.86E-08	46
47	SUFU	SUFU negative regulator of hedgehog signaling	1.139	-4.435	down	2.73E-55	47
48	HSD17B10	Hydroxysteroid 17-beta dehydrogenase 10	1.404	-4.104	down	0.00E+00	48
49	LARP7	La ribonucleoprotein 7, transcriptional regulator	1.99	4.669	up	1.66E-06	49
50	CHMP4B	Charged multivesicular body protein 4B	1.034	5.857	up	0.00E+00	50




Figure 10: Dysregulated gene from Lung sample, control and disease sample

Table 5: The DEGs of merged datasets from the Lung sample with the applied criteria of p-value <0.05 and |log2FC| ≥ 1.5, network score and directionality of regulations

Lung tissues							
#	Gene Symbol	Gene Name	Network Score	Gene Expression	Direction	p-value	Relative ranking
1	TNFSF13B	TNF superfamily member 13b	2.902	2.955	up	1.63E-07	1
2	ICOS	Inducible T cell costimulator	2.906	2.314	up	9.20E-03	2
3	HUWE1	HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1	2.171	-15.978	down	0.00E+00	3
4	LRRK2	Leucine rich repeat kinase 2	7.025	-14.834	down	4.09E-141	4
5	CREBBP	CREB binding protein	2.121	-15.198	down	7.35E-230	5
6	DDX17	DEAD-box helicase 17	1.414	-15.742	down	0.00E+00	6
7	BAZ1B	Bromodomain adjacent to zinc finger domain 1B	2.709	-14.784	down	7.80E-269	7
8	PLEKHA4	Pleckstrin homology domain containing A4	22.555	-14.334	down	5.10E-125	8
9	EPAS1	Endothelial PAS domain protein 1	1.303	-15.763	down	2.18E-117	9
10	MACF1	Microtubule actin crosslinking factor 1	1.123	-18.03	down	3.37E-298	10
11	MDN1	Midasin AAA ATPase 1	1.387	-15.107	down	2.95E-182	11
12	EP300	E1A binding protein p300	1.657	-14.678	down	5.87E-306	12
13	UPF2	UPF2 regulator of nonsense mediated mRNA decay	2.932	-14.233	down	1.48E-220	13
14	UBQLN1	UBQLN1	3.81	-14.09	down	1.15E-177	14
15	TAF15	TATA-box binding protein associated factor 15	1.302	-14.761	down	1.02E-285	15
16	DOCK5	Dedicator of cytokinesis 5	2.375	-14.166	down	1.41E-220	16
17	SMC3	Structural maintenance of chromosomes 3	3.775	-13.927	down	1.40E-209	17
18	USP9X	Ubiquitin specific peptidase 9 X-linked	1.494	-14.351	down	6.33E-282	18
19	WDR26	WD repeat domain 26	1.265	-14.726	down	5.68E-262	19
20	SORT1	Sortilin 1	0.953	-15.359	down	2.86E-278	20
21	HNRNPU	Heterogeneous nuclear ribonucleoprotein U	1.041	-15.208	down	1.06E-285	21
22	AKAP9	A-kinase anchoring protein 9	0.861	-15.63	down	1.50E-234	22
23	PIK3R1	Phosphoinositide-3-kinase regulatory subunit 1	0.835	-15.638	down	5.33E-227	23
24	TRIM33	Tripartite motif containing 33	2.772	-13.791	down	3.62E-178	24
25	SMAD2	SMAD family member 2	1.315	-14.264	down	7.46E-90	25
26	SUPT16H	SPT16 homolog, facilitates chromatin remodeling subunit	7.35	-13.645	down	2.29E-226	26
27	CHD7	Chromodomain helicase DNA binding protein 7	1.368	-14.129	down	1.61E-145	27
28	HNRNPD	Heterogeneous nuclear ribonucleoprotein D	0.785	-15.452	down	9.61E-276	28
29	YWHAE	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon	0.786	-15.188	down	1.73E-269	29
30	CDK12	Cyclin dependent kinase 12	0.889	-14.656	down	4.66E-177	30
31	MAP1LC3B	Microtubule associated protein 1 light chain 3 beta	3.492	-13.499	down	1.12E-236	31
32	CD81	CD81 molecule	0.847	-14.656	down	1.37E-273	32
33	PLEC	Plectin	0.638	-17.392	down	1.12E-246	33
34	SAMHD1	SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1	2.623	-13.501	down	3.19E-92	34
35	RPL36	Ribosomal protein L36	1.392	-13.731	down	5.16E-168	35
36	GRB2	Growth factor receptor bound protein 2	2.649	-13.447	down	1.18E-197	36
37	ACTG1	Actin gamma 1	0.584	-17.213	down	2.15E-258	37
38	KDM5B	Lysine demethylase 5B	1.643	-13.579	down	9.26E-177	38
39	PTPN11	Protein tyrosine phosphatase non-receptor type 11	1.076	-13.895	down	5.26E-303	39
40	UBC	Ubiquitin C	1.506	-13.536	down	1.05E-94	40

41	AFG3L2	AFG3 like matrix AAA peptidase subunit 2	3.387	-13.224	down	1.31E-141	41
42	ACTB	Actin beta	1.332	-13.624	down	4.62E-109	42
43	SRPK1	SRSF protein kinase 1	1.181	-13.693	down	1.47E-218	43
44	PRKDC	Protein kinase, DNA-activated, catalytic subunit	0.609	-15.145	down	1.51E-297	44
45	BICD2	BICD cargo adaptor 2	1.929	-13.299	down	4.50E-160	45
46	RAC1	Rac family small GTPase 1	0.752	-14.219	down	8.96E-284	46
47	IQGAP1	IQ motif containing GTPase activating protein 1	0.575	-15.243	down	0.00E+00	47
48	SBDS	SBDS ribosome maturation factor	2.001	-13.242	down	4.17E-173	48
49	MYBBP1A	MYB binding protein 1a	1.15	-13.633	down	1.80E-141	49
50	SUGT1	SGT1 homolog, MIS12 kinetochore complex assembly cochaperone	1.993	-13.218	down	6.72E-78	50

Cyclic adenosine monophosphate response element-binding protein (CREBBP) found significantly downregulated in our study with a -15.198 Log 2-fold change value and serves as a potential biomarker for SARS-CoV-2. The functions of CREBBP are involved in cholesterol biosynthesis and Insulin regulation [57]. Dysregulation of cholesterol biosynthesis of Insulin could be an interesting MoA that several studies suggested its functional role that may lead to the reduction of SARS-CoV-2 infections [58] and regulating the entry of the SARS-CoV-2 virus into the host cell [58,59].

Conclusion

Our study has summarized the transcriptomics analysis of Covid-19 HTS data from Blood, PBMC and Lung tissues. We have identified 139 common DEGs from PBMC and blood, 291 common DEGs from Lung and Blood and 326 common DEGs from Lung and Blood. Our functional and CoVint network analysis revealed that the most common DEG from blood, PBMC and Lung tissue is CREB3L1, SOX2, UBR4 and FLNC. We also identified that ITPA, DLG3, ING4, TECR, NADH, SMAD, HUWE1, DDX17 and CREBBP are highly downregulated and activation of these genes may play an important role in disease reversal. Similarly, inhibition of RELA, HPSE, TRIM33, and TNFSF13B can be further explored experimentally for better therapeutic development and benefit of Covid-19 patients. In summary, these hub genes can be considered potential therapeutic biomarkers for the diagnosis of SARS-CoV-2.

Funding: None

Conflict of interest: The authors declare no conflict of interest, financial or otherwise.

Acknowledgements

Author of this paper would like to thank Dr. Gunjan Bhardwaj, CEO and Founder of Partex NV, and Gaurav Tripathi, Co-founder of Innoplexus Consulting Pvt Ltd, for their continuous support and motivation during this project.

The author would also like to express gratitude to Komal Gowli and Aryamen Singh for their timely support in data sourcing and graph preparation. Additionally, sincere acknowledgments are extended to Mr. Holger Hoffman, Mr. Abhijit Keskar, and Mr. Amit Ananpara for their guidance, support, and provision of infrastructure facilities.

Data Availability Statement

Publicly available datasets were analyzed in this study. This data can be found here: COVID19 PBMC samples were retrieved from Gene Expression Omnibus (GEO) (<https://www.ncbi.nlm.nih.gov/geo>) with accession number GSE166253 and GSE152418, accession number GSE150316. The whole blood RNA-seq dataset accession number is GSE185557, GSE166190, GSE169687, GSE161731 and GSE161777 and the COVID-19 lung RNA-seq dataset was retrieved from GSE151764 and GSE150316.

Author Contributions

O.S were responsible for the conception, design, and development of the methodology. RS was responsible for executing and identification of DEGs analysis. V.C was responsible for preparing CoVint internetwork. O.S performed, detailed analysis and validation of DEGs and overall scoring and hypothesis generation. O.S was responsible for the overall supervision of the study and writing the manuscript. All authors contributed to the article and approved the submitted version.

References

1. Roshdy A, Zaher S, Fayed H & Coghlan JG. COVID-19 and the Heart: A Systematic Review of Cardiac Autopsies. *Front Cardiovasc Med* 7 (2020): 626975.
2. Mokhtari T. et al. COVID-19 and multiorgan failure: A narrative review on potential mechanisms. *J. Mol. Histol* 51 (2020): 613–628.
3. Hoffmann M. et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic *Cell* 185 (2022): 447–456.e11.

4. Hyland P. et al. Resistance to COVID-19 vaccination has increased in Ireland and the United Kingdom during the pandemic. *Public Health* 195 (2021): 54–56.
5. Wang R, Chen J & Wei G-W. Mechanisms of SARS-CoV-2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America. *J. Phys. Chem. Lett* 12 (2021): 11850–11857.
6. CovMT: an interactive SARS-CoV-2 mutation tracker, with a focus on critical variants. *Lancet Infect. Dis* 21 (2021): 602.
7. Kannan S, Shaik Syed Ali P & Sheeza A. Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review. *Eur. Rev. Med. Pharmacol. Sci* 25 (2021): 8019–8022.
8. The Lancet Infectious Diseases. Unmet need for COVID-19 therapies in community settings. *Lancet Infect. Dis* 21 (2021): 1471.
9. di Iulio J, Bartha I, Spreafico R, Virgin HW & Telenti A. Transfer transcriptomic signatures for infectious diseases. *Proc. Natl. Acad. Sci. U. S. A* 118 (2021).
10. Barrett T. et al. NCBI GEO: archive for functional genomics data sets--update. *Nucleic Acids Res* 41 (2013): D991–5.
11. FelixKrueger. GitHub - FelixKrueger/TrimGalore: A wrapper around Cutadapt and FastQC to consistently apply adapter and quality trimming to FastQ files, with extra functionality for RRBS data.
12. Patro R, Duggal G, Love MI, Irizarry RA & Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. *Nat. Methods* 14 (2017): 417–419.
13. Love MI, Huber W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 15 (2014): 550.
14. Sharma OP, Seiz W & Scheele J. SARS-CoV-2 therapeutic landscape, opportunity and future threats. *The Open COVID Journal* 1 (2021): 205–215.
15. Mallick, I. et al. In-silico identification and prioritization of therapeutic targets of asthma. *Sci. Rep* 13 (2023): 15706.
16. Ontosight® Explore. <https://www.innoplexus.com/life-science-ai-products-solutions/ontosight-xplore/> (2018).
17. United States Patent Application: 0200090789.
18. Ostaszewski M. et al. COVID19 Disease Map, a computational knowledge repository of virus-host interaction mechanisms. *Mol. Syst. Biol* 17 (2021): e10387.
19. Ashburner M. et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat. Genet* 25 (2000): 25–29.
20. Ritchie ME. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* 43 (2015): e47.
21. Luo J. et al. The potential involvement of JAK-STAT signaling pathway in the COVID-19 infection assisted by ACE2. *Gene* 768 (2021): 145325.
22. Farahani M. et al. Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets. *Biomed. Pharmacother* 145 (2022): 112420.
23. Mohanta TK, Sharma N, Arina P & Defilippi P. Molecular Insights into the MAPK Cascade during Viral Infection: Potential Crosstalk between HCQ and HCQ Analogues. *Biomed Res. Int* (2020): 8827752.
24. Khalil BA, Elemam NM & Maghazachi AA. Chemokines and chemokine receptors during COVID-19 infection. *Comput. Struct. Biotechnol. J* 19 (2021): 976–988.
25. Giacomelli C, Piccarducci R, Marchetti L, Romei C & Martini C. Pulmonary fibrosis from molecular mechanisms to therapeutic interventions: lessons from post-COVID-19 patients. *Biochem. Pharmacol* 193 (2021): 114812.
26. Kiener M. et al. Human-Based Advanced Approaches to Investigate Lung Fibrosis and Pulmonary Effects of COVID-19. *Front. Med* 8 (2021): 644678.
27. Greenwood M, Greenwood MP, Paton JFR & Murphy D. Transcription Factor CREB3L1 Regulates Endoplasmic Reticulum Stress Response Genes in the Osmotically Challenged Rat Hypothalamus. *PLoS One* 10 (2015): e0124956.
28. Sajuthi SP, et al. Type 2 and interferon inflammation strongly regulate SARS-CoV-2 related gene expression in the airway epithelium. *bioRxiv* (2020).
29. Zhang Z. et al. Clinical analysis and pluripotent stem cells-based model reveal possible impacts of ACE2 and lung progenitor cells on infants vulnerable to COVID-19. *Theranostics* 11 (2021): 2170–2181.
30. Tiwari SK, Wang S, Smith D, Carlin AF & Rana TM. Revealing Tissue-Specific SARS-CoV-2 Infection and Host Responses using Human Stem Cell-Derived Lung and Cerebral Organoids. *Stem Cell Reports* 16 (2021): 437–445.
31. Sano E. et al. Modeling SARS-CoV-2 infection and its individual differences with ACE2-expressing human iPS cells. *iScience* 24 (2021): 102428.
32. Lee C-J. et al. Crosstalk between SOX2 and cytokine signaling in endometrial carcinoma. *Sci Rep* 8 (2018): 17550.

33. Li S-W. et al. Severe acute respiratory syndrome coronavirus papain-like protease suppressed alpha interferon-induced responses through downregulation of extracellular signal-regulated kinase 1-mediated signalling pathways. *J. Gen. Virol* 92 (2011): 1127–1140.
34. Page C. et al. Induction of alternatively activated macrophages enhances pathogenesis during severe acute respiratory syndrome coronavirus infection. *J. Virol* 86 (2012): 13334–13349.
35. Almasy KM, Davies JP & Plate L. Comparative host interactomes of the SARS-CoV-2 nonstructural protein 3 and human coronavirus homologs. *bioRxiv* (2021).
36. Tripathi S. et al. Meta- and Orthogonal Integration of Influenza ‘OMICs’ Data Defines a Role for UBR4 in Virus Budding. *Cell Host Microbe* 18 (2015): 723–735.
37. Al-Eitan LN, & Alahmad SZ. Pharmacogenomics of genetic polymorphism within the genes responsible for SARS-CoV-2 susceptibility and the drug-metabolising genes used in treatment. *Rev. Med Virol* 31 (2021): e2194.
38. Caillet-Saguy C. et al. Host PDZ-containing proteins targeted by SARS-CoV-2. *FEBS J* 288 (2021): 5148–5162.
39. Yin X. et al. MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells. *Cell Rep* 34 (2021): 108628.
40. Shi C. et al. The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID-19 Patients: A Retrospective Cohort Study. *Clin. Transl. Sci* 13 (2020): 1087–1095.
41. Kiyani Y. et al. Heparanase-2 protects from LPS-mediated endothelial injury by inhibiting TLR4 signalling. *Sci. Rep* 9 (2019): 13591.
42. Ali H, et al. Cellular TRIM33 restrains HIV-1 infection by targeting viral integrase for proteasomal degradation. *Nat. Commun* 10 (2019): 926.
43. Martonik D, Parfieniuk-Kowerda A, Rogalska M, & Flisiak R. The Role of Th17 Response in COVID-19 Cells 10 (2021).
44. Tanaka S. et al. Trim33 mediates the proinflammatory function of Th17 cells. *J Exp Med* 215 (2018): 1853–1868.
45. Vaz de Paula CB. et al. COVID-19: Immunohistochemical Analysis of TGF- β Signaling Pathways in Pulmonary Fibrosis. *Int J Mol Sci* 23 (2021).
46. Gelarden I. et al. Comprehensive evaluation of bronchoalveolar lavage from patients with severe COVID-19 and correlation with clinical outcomes. *Hum. Pathol* 113 (2021): 92–103.
47. Sosa-Hernández VA, et al. B Cell Subsets as Severity-Associated Signatures in COVID-19 Patients. *Front. Immunol* 11 (2020): 611004.
48. Cui D. et al. Follicular Helper T Cells in the Immunopathogenesis of SARS-CoV-2 Infection. *Front. Immunol* 12 (2021): 731100.
49. Hutloff A. Regulation of T follicular helper cells by ICOS. *Oncotarget* 6 (2015): 21785–21786.
50. Huang X. et al. The ubiquitin ligase Peli1 inhibits ICOS and thereby Tfh-mediated immunity. *Cell. Mol. Immunol* 18 (2021): 969–978.
51. Weber JP, et al. ICOS maintains the T follicular helper cell phenotype by down-regulating Krüppel-like factor 2. *J. Exp Med* 212 (2015): 217–233.
52. Zhong Q, Gao W, Du F & Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. *Cell* 121 (2005): 1085–1095.
53. Parsons JL, et al. Ubiquitin ligase ARF-BP1/Mule modulates base excision repair. *EMBO J* 28 (2009): 3207–3215.
54. Yoon SY. et al. Over-expression of human UREB1 in colorectal cancer: HECT domain of human UREB1 inhibits the activity of tumor suppressor p53 protein. *Biochem. Biophys. Res. Commun* 326 (2005): 7–17.
55. Zhou Y, et al. Host E3 ligase HUWE1 attenuates the proapoptotic activity of the MERS-CoV accessory protein ORF3 by promoting its ubiquitin-dependent degradation. *J. Biol Chem* 298 (2022): 101584.
56. Poloznikov AA, et al. HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons. *Front. Pharmacol* 11 (2020): 621054.
57. Zhou XY. et al. Insulin regulation of hepatic gluconeogenesis through phosphorylation of CREB-binding protein. *Nat. Med* 10 (2004): 633–637.
58. Ziegler CGK, et al. Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19. *bioRxiv* (2021).
59. Kočar E, Režen T & Rozman D. Cholesterol, lipoproteins, and COVID-19: Basic concepts and clinical applications. *Biochim. Biophys. Acta Mol. Cell Biol Lipids* 1866 (2021): 158849.